The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, ...
Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing ...
As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...
News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to ...
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...
News Medical on MSN20h
New guidance balances GLP-1 risks and benefits for surgeryMost patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and gastrointestinal endoscopies, according to new clinical ...
A large retrospective study, the first of its kind, reported reduced rates of EO-CRC in patients younger than 50 years of age ...
When food enters the digestive system, specialized cells in the small intestine release GLP-1, initiating a cascade of ...
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...
Most patients should not stop taking GLP-1 receptor agonists prior to elective surgery, according to updated guidance from several medical societies, including the American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback